Evidence map›Paper›PMID 30765424›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2019

Acetylcholine Inhibits Platelet Activation.

John A Bennett, Sara K Ture, Rachel A Schmidt, Michael A Mastrangelo, Scott J Cameron, Lara E Terry, David I Yule, Craig N Morrell, Charles J Lowenstein

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. GENETIC DETERMINANTS OF THROMBOSIS.Transactions of the American Clinical and Climatological Association · 2024
    Article
  4. Editorial: COVID-19 and thrombo-inflammatory responses.Frontiers in cardiovascular medicine · 2023
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

John A BennettAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York johna_bennett@urmc.rochester.edu.
Sara K TureAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York.
Rachel A SchmidtAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York.
Michael A MastrangeloAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York.
Scott J CameronAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York.
Lara E TerryAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York.
David I YuleAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York.
Craig N MorrellAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York.
Charles J LowensteinAab Cardiovascular Research Institute, Department of Medicine (J.A.B., S.K.T., R.A.S., M.A.M., S.J.C., C.N.M., C.J.L.) and Department of Pharmacology and Physiology (L.E.T., D.I.Y.), University of Rochester Medical Center, Rochester, New York.
University of Rochester Medical Center · US

Funding

[Ca2+]i and Secretory Dynamics in Parotid Acinar CellsR01DE014756 · NIDCR · UNIVERSITY OF ROCHESTER · PI David I Yule · 2002 to 2026
$9.9M
An experimental/computational approach for understanding salivary fluid secretionR01DE019245 · NIDCR · UNIVERSITY OF ROCHESTER · PI David I Yule · 2008 to 2026
$9.7M
RESEARCH TRAINING IN PREVENTIVE CARDIOLOGYT32HL007937 · NHLBI · UNIVERSITY OF ROCHESTER · PI LOWENSTEIN, CHARLES J · 2000 to 2014
$7.1M
Population genomic variation, functional biology, and the risk of venous thrombosisR01HL134894 · NHLBI · UNIVERSITY OF WASHINGTON · PI LOWENSTEIN, CHARLES J, SMITH, NICHOLAS L · 2017 to 2020
$2.9M
Novel platelet functions for in T-cell helper cell responsesR01HL124018 · NHLBI · UNIVERSITY OF ROCHESTER · PI MORRELL, CRAIG N · 2015 to 2018
$1.5M
Model system of oral contraceptive-induced VTE: integrating genomic, transcriptomic, and proteomic discovery with functional biologyR61HL141791 · NHLBI · UNIVERSITY OF ROCHESTER · PI LOWENSTEIN, CHARLES J, SMITH, NICHOLAS L · 2018 to 2019
$1.4M
Exocytosis and Vascular InflammationR01HL078635 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI LOWENSTEIN, CHARLES J · 2004 to 2007
$1.3M
Platelet ERK5 regulates myocardial infarct expansionK08HL128856 · NHLBI · UNIVERSITY OF ROCHESTER · PI CAMERON, SCOTT JAMES · 2016 to 2020
$775k
NHLBI NIH HHS K08 HL128856NHLBI NIH HHS R01 HL078635NHLBI NIH HHS R01 HL124018NHLBI NIH HHS R01 HL134894NHLBI NIH HHS R61 HL141791NHLBI NIH HHS T32 HL007937NIDCR NIH HHS R01 DE014756NIDCR NIH HHS R01 DE019245
6 · The paper itself

Abstract

Platelets are key mediators of thrombosis. Many agonists of platelet activation are known, but fewer endogenous inhibitors of platelets, such as prostacyclin and nitric oxide (NO), have been identified. Acetylcholinesterase inhibitors, such as donepezil, can cause bleeding in patients, but the underlying mechanisms are not well understood. We hypothesized that acetylcholine is an endogenous inhibitor of platelets. We measured the effect of acetylcholine or analogs of acetylcholine on human platelet activation ex vivo. Acetylcholine and analogs of acetylcholine inhibited platelet activation, as measured by P-selectin translocation and glycoprotein IIb IIIa conformational changes. Conversely, we found that antagonists of the acetylcholine receptor, such as pancuronium, enhance platelet activation. Furthermore, drugs inhibiting acetylcholinesterase, such as donepezil, also inhibit platelet activation, suggesting that platelets release acetylcholine. We found that NO mediates acetylcholine inhibition of platelets. Our data suggest that acetylcholine is an endogenous inhibitor of platelet activation. The cholinergic system may be a novel target for antithrombotic therapies.

Indexed as

AcetylcholineBlood PlateletsHumansNitric OxidePlatelet ActivationReceptors, CholinergicAcetylcholineNitric OxideReceptors, Cholinergic

Identifiers

PMID30765424
PMCPMC6439456
OpenAlexW2911869463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.